Chromophobic is a term from pathology that literally means “color-fearing” or, more practically, resistant to staining. When a pathologist applies dyes to a tissue sample under a microscope, most cells soak up those dyes and turn vivid shades of pink, blue, or purple. Chromophobic cells do not. They remain pale or washed-out, and that refusal to absorb color is what gives them their name. The term shows up most often in two medical contexts: certain cells in the pituitary gland and a specific subtype of kidney cancer called chromophobe renal cell carcinoma.
Why Some Cells Refuse to Stain
Standard tissue staining in a pathology lab works because cellular structures have a chemical affinity for particular dyes. Proteins, nucleic acids, and other molecules grab onto the dye and hold it, producing the familiar blues and pinks of a stained slide. Chromophobic cells lack the dense concentrations of these dye-binding molecules. In many cases, the cytoplasm of a chromophobic cell is filled with tiny bubble-like structures called microvesicles rather than the protein-packed granules that absorb stain easily. The result is a cell that looks distinctly pale or translucent compared to its neighbors.
In the pituitary gland, for instance, pathologists have long classified hormone-producing cells by their staining behavior. Acidophilic cells stain with acidic dyes, basophilic cells stain with basic dyes, and chromophobic cells stain with neither. Early pituitary research leaned heavily on this classification. When special stains and electron microscopy became available, researchers found that many so-called chromophobe pituitary adenomas actually contained cells with well-developed protein-making machinery and secretory granules up to 500 micrometers across, just not granules dense enough to absorb standard stains reliably.1PubMed. Definition and differential diagnosis of chromophobe pituitary adenomas: light and electron microscopic studies That discovery reshaped how pathologists think about these tumors: the staining behavior was a clue, but not the whole story.
Chromophobe Renal Cell Carcinoma
The most clinically significant use of “chromophobic” today involves a kidney cancer subtype. Chromophobe renal cell carcinoma, often abbreviated ChRCC, accounts for roughly 5% of all kidney cancers. It was first described as a distinct entity in the 1980s, when pathologists noticed that some kidney tumors had cells with an unusual pale, washed-out cytoplasm that resisted conventional staining. Under the microscope, the tumor cells arrange themselves in solid sheets and have prominent cell borders, pale to pinkish cytoplasm, and wrinkled nuclei sometimes described as “raisinoid.”2Asian Journal of Urology. Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates Another hallmark is a perinuclear halo, a ring of clearing around the nucleus that gives the cells a distinctive look.3PubMed. Microscopic and nuclear morphometric findings of chromophobe renal cell carcinoma, renal oncocytoma, and tumor with overlapping histology
ChRCC comes in two main flavors. The classic variant has the pale, transparent cells that give the tumor its name. The eosinophilic variant has cells packed with more mitochondria, which makes them stain pinkish, sometimes closely mimicking another kidney tumor called renal oncocytoma.4PubMed Central. Chromophobe renal cell carcinoma or oncocytoma: a manner of challenge in frozen section diagnosis This overlap causes real diagnostic headaches, because oncocytomas are benign and ChRCCs are malignant. Getting it wrong can mean the difference between watchful waiting and surgery.
How Pathologists Tell It Apart from Look-Alikes
Because the eosinophilic variant of ChRCC can so closely resemble an oncocytoma, pathologists rely on multiple tools beyond basic microscopy. One classic technique is the Hale’s colloidal iron stain. In ChRCC, this stain produces a strong, diffuse, net-like (reticular) pattern throughout the cytoplasm. In one study, that pattern appeared in all 14 chromophobe cases tested and in none of the other kidney tumor types.5PubMed. Colloidal iron staining in renal epithelial neoplasms, including chromophobe renal cell carcinoma: emphasis on technique and patterns of staining Oncocytomas can also show some colloidal iron positivity, but the staining pattern is different: focal and concentrated near the membrane or nucleus rather than spread throughout the cell.6PubMed. Renal oncocytoma and chromophobe renal cell carcinoma. A comparison of colloidal iron staining and electron microscopy
Modern pathology has added immunohistochemistry to the toolkit. ChRCC has a characteristic staining fingerprint: it is typically positive for cytokeratin-7 (CK7), CD117, and claudin-7, while being negative for vimentin. Clear cell renal carcinoma, the most common kidney cancer, has the opposite profile: vimentin-positive and CK7-negative.7Journal of Microscopy and Ultrastructure. Diagnostic utility of vimentin, CD117, cytokeratin-7 and caveolin-1 in differentiation between clear cell renal cell carcinoma, chromophobe renal cell carcinoma and oncocytoma When pathologists combine all three “7” markers (CK7, CD117, and claudin-7), the specificity for identifying ChRCC reaches 100% in at least one institutional study, meaning no other kidney tumor type tested positive for all three together.8PubMed Central. Combined Immunohistochemistry for the “Three 7” Markers (CK7, CD117, and Claudin-7) Is Useful in the Diagnosis of Chromophobe Renal Cell Carcinoma and for the Exclusion of Mimics The practical value here is that a panel of stains can resolve ambiguity that a single stain or basic microscopy cannot.
Where These Tumors Come From
A question that interested researchers for decades was which normal kidney cell gives rise to ChRCC. As early as 1989, ultrastructural studies pointed to intercalated cells of the kidney’s collecting duct system, the tubes deep in the kidney that fine-tune urine composition.9PubMed. The human chromophobe cell renal carcinoma: its probable relation to intercalated cells of the collecting duct More recent work using gene expression profiling has confirmed that connection. When researchers compared the molecular signatures of ChRCC to those of various normal kidney cell types, the closest match was consistently with a specific subpopulation of intercalated cells.10Cancer Cell. Chromophobe renal cell carcinoma Single-cell analyses showed similarity scores between ChRCC and intercalated cells ranging from 0.60 to 0.80.11PubMed Central. Characterization of the Cellular Origin and Oncogenic Mechanisms of Chromophobe Renal Cell Carcinoma (ChRCC) and Renal Oncocytic Neoplasms
This matters because the cell of origin helps explain ChRCC’s unusual biology. Intercalated cells are specialized acid-base regulators loaded with mitochondria and ion transport proteins. That heritage shows up in the tumor: ChRCC cells are rich in mitochondria (especially the eosinophilic variant) and have metabolic quirks distinct from clear cell kidney cancer, which arises from a different part of the nephron entirely.
The Genetic Landscape
ChRCC has a genetic signature unlike any other kidney cancer. Where clear cell carcinoma is defined by loss of part of chromosome 3, ChRCC typically involves the loss of entire chromosomes, often including chromosomes 1, 2, 6, 10, 13, and 17. Early cytogenetic work also identified losses of genetic material at chromosomal regions 3p, 5q, 17p, and 17q, a combination not found in other renal tumor types.12PubMed. Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinomas Mitochondrial DNA is also frequently disrupted, with loss-of-function mutations appearing in genes that encode components of the cell’s energy-producing machinery.13PubMed Central. Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies
The mutation burden in ChRCC is generally low compared to many other solid tumors, which has implications for treatment. Tumors with fewer mutations tend to produce fewer abnormal proteins on their surface, giving the immune system less to recognize and attack. This helps explain why ChRCC is often resistant to immunotherapy, a point we will return to.
Prognosis Compared to Other Kidney Cancers
If you or someone you know has been diagnosed with ChRCC, the prognosis is generally more favorable than for the most common type of kidney cancer, clear cell carcinoma. In a large cohort study, the five-year cancer-specific survival rate for ChRCC was about 87%, compared with roughly 69% for clear cell carcinoma.14PubMed. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma A meta-analysis pooling data from ten studies confirmed that ChRCC patients had roughly half the risk of death from their cancer compared to clear cell patients after adjusting for other factors.15PubMed. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? Survival was similar between ChRCC and papillary renal cell carcinoma, the other major subtype.
There is an important caveat. When ChRCC does metastasize, particularly to the lungs, the picture darkens considerably. One study found that among patients with lung metastases, median survival was about 14 months for ChRCC versus about 25 months for clear cell carcinoma, a reversal of the usual pattern.16JAMA Network Open. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival The reason may be partly that metastatic ChRCC responds poorly to the drugs that work against metastatic clear cell disease, leaving fewer effective treatment options once the cancer has spread.
When Chromophobe Tumors Turn Aggressive
A small fraction of ChRCCs undergo what is called sarcomatoid differentiation, where part of the tumor transforms into a high-grade, spindle-shaped pattern that behaves much more aggressively. The sarcomatoid component and the conventional ChRCC component can sit side by side in the same tumor, and genomic sequencing of the two areas reveals distinct differences: the sarcomatoid portion carries additional chromosomal gains, new single-nucleotide variants, and gene fusions not present in the conventional portion.17PubMed Central. Chromophobe renal cell carcinoma with sarcomatoid change: A case report Patients whose tumors had a larger percentage of sarcomatoid tissue tended to have bigger tumors at diagnosis and shorter survival.18PubMed Central. Chromophobe Renal Cell carcinoma with Sarcomatoid Differentiation
One molecular detail worth noting: in at least one case, the sarcomatoid portion of the tumor expressed PD-L1 (the protein that immune checkpoint drugs target) on more than 10% of tumor cells, while the conventional ChRCC portion was PD-L1 negative.19PubMed Central. Chromophobe renal cell carcinoma with sarcomatoid change: A case report That raises the question of whether sarcomatoid ChRCC might respond differently to immunotherapy than pure ChRCC, though data are still extremely limited.
The Hereditary Link to Birt-Hogg-Dubé Syndrome
Most ChRCC cases are sporadic, meaning they arise without an inherited genetic predisposition. But there is one hereditary syndrome where chromophobe tumors appear with striking frequency: Birt-Hogg-Dubé syndrome, or BHD. This rare condition is caused by mutations in a gene called FLCN and produces a triad of skin bumps (fibrofolliculomas), lung cysts that can cause spontaneous collapsed lungs, and kidney tumors.20PubMed. The ABCs of BHD: An In-Depth Review of Birt-Hogg-Dubé Syndrome
The kidney tumors in BHD are often multiple and bilateral, appearing in both kidneys simultaneously. In one study examining 130 resected tumors from BHD patients, about a third were pure chromophobe renal cell carcinomas, and half were hybrid tumors blending features of chromophobe carcinoma and oncocytoma.21PubMed. Renal tumors in the Birt-Hogg-Dubé syndrome A case report illustrating the syndrome described a patient with bilateral hybrid tumors and a unilateral chromophobe carcinoma, along with a history of prior pneumothorax surgery; genetic testing confirmed a nonsense mutation in the FLCN gene.22PubMed Central. Heterozygous germline FLCN mutation in Birt-Hogg-Dubé syndrome with bilateral renal hybrid oncocytic/chromophobe tumor and unilateral renal chromophobe cell carcinoma For younger patients who present with multiple kidney tumors, or kidney tumors paired with unexplained lung problems, BHD is a diagnosis worth investigating through genetic testing.
Why Standard Treatments Fall Short
Treating localized ChRCC is straightforward: surgery, either removing the entire kidney or just the tumor, is curative for most patients. The problem arises when the cancer has spread. The targeted drugs and immunotherapies that have transformed outcomes for metastatic clear cell kidney cancer perform poorly against ChRCC.
A systematic review of available evidence found that ChRCC appears resistant to immune checkpoint inhibitors, with only a handful of tumor responses observed across published studies.23Urologic Oncology: Seminars and Original Investigations. Systemic therapy for chromophobe renal cell carcinoma: A systematic review The biological explanation is becoming clearer. Single-cell analyses show that ChRCC tumors have strikingly few immune cells infiltrating them, especially the cytotoxic T cells that checkpoint drugs aim to activate. The T cells that are present tend to show low expression of the checkpoint proteins that these drugs block, and many are “bystander” cells with no apparent ability to recognize the tumor.24PubMed Central. Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma Further, only about 5% of ChRCC tumor cells express PD-L1, the main protein that checkpoint drugs are designed to counteract.25Cancer Cell. Chromophobe renal cell carcinoma
That does not mean there is zero hope. Individual case reports suggest some patients may benefit from combination regimens. One report described a patient with metastatic ChRCC who received an immune checkpoint inhibitor (sintilimab) combined with a targeted anti-angiogenic drug (axitinib) as second-line treatment. The lung lesions gradually shrank, and the patient remained on treatment for over two years.26PubMed Central. Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report A single case report is far from a proven therapy, but it signals a direction worth testing in clinical trials. For now, the treatment landscape for advanced ChRCC remains frustratingly limited compared to its clear cell counterpart.
Imaging Clues Before a Biopsy
Radiologists can sometimes suspect a chromophobe tumor before tissue is ever obtained. On MRI, different kidney tumor subtypes behave differently when contrast dye is injected. Clear cell carcinomas are highly vascular and light up brightly on early contrast-enhanced images. Chromophobe tumors, by contrast, enhance much less. In one study, clear cell tumors showed a mean relative signal intensity of about 2.9 compared to surrounding kidney tissue in the early contrast phase, while chromophobe tumors measured around negative 21.0, meaning they were actually darker than the normal kidney around them.27PubMed. Performance of Relative Enhancement on Multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) From Papillary and Chromophobe RCC Subtypes and Oncocytoma The pattern is not diagnostic on its own, but it can steer clinical suspicion and help plan the surgical approach.
Chromophobic Cells Beyond the Kidney
Though kidney cancer dominates the clinical conversation around “chromophobic,” the concept extends to other tissues. In veterinary pathology, pituitary tumors in dogs are evaluated with similar staining-based classifications. A study examining canine pituitary glands found that proliferative lesions were often sparsely to densely granulated, with granules described as basophilic to chromophobic.28PubMed. Histopathologic Findings in Canine Pituitary Glands The same principle applies: the cells resist standard dyes because their internal granules lack the density or chemical composition to hold onto color.
In electron microscopy studies of the pituitary, what were once lumped together as “chromophobe adenomas” turned out to be a mixed group. About half contained well-developed protein-synthesizing structures, suggesting they were actively making hormones despite looking inactive under the light microscope. Another quarter were loaded with self-digesting structures or lipid droplets.29PubMed. Definition and differential diagnosis of chromophobe pituitary adenomas: light and electron microscopic studies The lesson that emerged from both pituitary and kidney pathology is the same: chromophobic is a description of how a cell looks under one set of conditions, not a final verdict on what the cell is doing. Newer molecular tools have repeatedly revealed active biology hiding behind that pale, unassuming appearance.